Genspect’s Response to NHS England Children’s Gender Service Consultation
By Genspect UK
NHS England is currently consulting on a revised service specification for children and young people’s gender services, following the Cass Review. The public consultation closes Sunday, November 2nd, 2025.
We encourage everyone to respond to the consultation: https://www.engage.england.nhs.uk/consultation/nhs-children-and-young-peoples-gender-service-spec/
Below is Genspect’s submission, drawing on evidence from our Beyond Trans service, which has conducted over 600 meetings with more than 480 detransitioners and those questioning transition from 43 countries.
3. To what extent do you support the inclusion of the holistic assessment of needs (Appendix A in the service specification)?
Partially Agree
We support comprehensive assessment but the conceptual framework is fundamentally flawed. The specification treats trauma, mental health conditions, autism, and same-sex attraction as “factors influencing gender-related distress” rather than recognizing these may be the primary issues, with gender distress as symptom or coping mechanism.
Through our Beyond Trans service—which has conducted over 600 meetings with 480+ participants from 43 countries—we encounter this pattern repeatedly. Young women whose sexual abuse histories were noted then never therapeutically addressed. Autistic individuals whose discomfort with social expectations was interpreted as evidence they were “born in the wrong body.” Young lesbians told their attraction to women meant they were “really trans men” rather than being supported to accept their sexuality.
In each case, trauma, autism, and internalized homophobia were not complications of gender identity but the fundamental problems. When these receive appropriate intervention, gender distress frequently resolves entirely because it was a manifestation of underlying issues rather than a separate condition requiring medical treatment.
The specification assumes that after addressing complicating factors, core gender incongruence will remain. This predetermined endpoint undermines differential diagnosis. Genuine assessment remains open to the conclusion that when trauma is processed, autism-related difficulties properly supported, and internalized homophobia resolved, gender distress disappears.
Neither ICD-11 “gender incongruence” nor DSM-5 “gender dysphoria” provides coherent medical diagnosis with clear treatment rationale. These are descriptive categories, not explanatory frameworks. Clinicians must retain freedom to conclude gender presentations are better understood through trauma, neurodevelopmental, mental health, or sexual orientation frameworks. Assessment should explore causation genuinely rather than filtering complications to isolate presumed gender identity requiring affirmation or medical intervention.
4. To what extent do you agree with the approach to the management of patients accessing prescriptions from unregulated sources?
Agree
We strongly agree the Service must not assume responsibility for prescriptions from unregulated sources or private providers operating outside NHS protocols. This is a child safeguarding issue requiring robust intervention.
However, Appendix A of the clinical commissioning policy for cross-sex hormones allows continuation of prescribing under certain conditions, directly contradicting the specification’s stated position. This contradiction must be eliminated immediately.
When children access hormones from unregulated sources, or adults procure these medications for children outside medical oversight, this represents serious safeguarding concern. Immediate referrals to appropriate authorities including social services must be mandatory. The specification should explicitly state clinicians’ reporting responsibilities, making clear that any prescription obtained outside regulated oversight triggers safeguarding protocols.
5a. To what extent do you support the description of the role and function of the National Provider Network?
Partially Agree
The National Provider Network serves essential functions for systematic data collection, audit, and establishing consistent clinical standards. However, robust institutional safeguards are critical to prevent ideological capture and silencing culture that characterized Tavistock GIDS, where clinicians raising concerns faced professional repercussions.
The specification must include explicit whistleblowing protections and clear mechanisms for clinicians to raise concerns about clinical practice, ideology-driven care, or patient outcomes without fear of consequences. Independent oversight must ensure clinical decisions are driven by evidence rather than ideology.
We are deeply concerned that the March 2025 specification included plans for “well-structured research programmes through a National Children and Young People’s Gender Incongruence Research Oversight Board” examining epidemiology, prediction, developmental course, and psychosocial intervention outcomes. This entire research framework was removed from the August specification without explanation.
Removing this research infrastructure is particularly concerning because NHS England appears intent on implementing services without systematic outcome data collection, exposing children to interventions that lack an evidence base. Research into psychosocial intervention effectiveness is essential and long overdue. Understanding which therapeutic approaches best support young people in addressing distress root causes would inform genuinely helpful practice. This research framework should be reinstated and prioritized.
5d. To what extent do you support the inclusion of endocrinology as a core function within the Multi-disciplinary Team?
Disagree
Endocrinology should not be core MDT function because medical intervention is inappropriate for gender-related distress in minors. The clinical commissioning policy is fundamentally flawed, published three weeks before the Cass Review and incorporating none of its findings. It claims evidence review but contains none, relying on 2017 Endocrine Society guidelines derived from 2012 WPATH standards without independent synthesis.
Cass Recommendation 8 required “clear clinical rationale for providing hormones at this stage rather than waiting until 18.” The policy provides no such rationale. NICE (2020) found very low certainty evidence with safety concerns. Cass found gender incongruence diagnoses have poor predictive power, particularly for adolescent females.
Evidence from Beyond Trans:
Our Beyond Trans service has worked with 480+ detransitioners across 43 countries. Among our cohort: 83% experience regret and doubt; 42% report medical complications; 77% took hormones; 31% had chest surgery; 47% experience suicidal ideation; 24% are estranged from family.
The consistent pattern: trauma, autism, mental health conditions, and internalized homophobia were inadequately explored before intervention. Service users describe clinicians “rolling out the red carpet” for transition rather than investigating distress. One said: “When I transitioned, I outsourced my autonomy to my therapist.” Another: “The doctor explained being trans as neurological.” One stated: “I was a baby, really.”
Young people needing trauma therapy received testosterone. Autistic youth needing support as their sex received surgery. Same-sex attracted teens received medical transition potentially representing flight from homosexuality.
Many face permanent changes: fertility loss, sexual dysfunction, chronic pain, unknown health effects. Some never experienced natural puberty, describing themselves as “walking experiments.” Healthcare providers who facilitated transition now dismiss their complications. They encounter clinicians asking “what pronoun are you?” rather than addressing harm.
Gender distress is psychological and social, arising from trauma, neurodevelopmental conditions, mental health issues, internalized homophobia, social influences. Medical intervention during adolescence disrupts normal development based on temporary states during identity exploration.
The specification removed puberty blockers for “limited evidence about safety, risks, benefits and outcomes.” This exact rationale applies to cross-sex hormones. Cass raised identical concerns. No principled basis exists for removing one experimental pathway while retaining another with equivalent evidentiary weaknesses plus 83% regret evidence.
If endocrinologists participate, their role should be strictly educational: explaining how disrupting healthy endocrine function causes permanent changes and why this is inappropriate for treating psychological distress in minors.
5e. To what extent do you support the separate pathway for pre-pubertal children?
Partially Agree
A distinct pathway for pre-pubertal children is appropriate given different clinical presentation and well-documented high rates of natural desistance. Research demonstrates most pre-pubertal children expressing gender-related concerns naturally reconcile with biological sex through normal development, particularly after experiencing puberty.
However, the specification’s treatment of social transition is problematic, conflating gender-nonconforming behavior with socially transitioning to live as the opposite sex. These are fundamentally different phenomena with vastly different implications.
A girl preferring activities stereotypically associated with boys, or a boy enjoying activities stereotypically associated with girls, is simply a gender-nonconforming child exhibiting normal developmental variation. Gender nonconformity requires no clinical intervention whatsoever.
Social transition is qualitatively different. It involves adopting opposite-sex names and pronouns, presenting as opposite sex across all social contexts, being treated by others as if one were the opposite sex, and often includes school policies obscuring the child’s sex from peers. This is not neutral exploration but active intervention with documented psychological and social consequences.
The Cass Review explicitly warned early social transition may foreclose natural developmental pathways along which distress would otherwise resolve. Parents require accurate, evidence-based information about documented risks rather than activist reassurances.
Furthermore, social transition necessarily affects schools, sports participation, residential settings, and other contexts where all children’s safety, privacy, and dignity must be protected. The specification entirely omits consideration of these institutional implications and rights of other children affected by accommodation policies. This represents serious oversight requiring correction.
7. Are there any other changes or additions to the revised service specification that should be considered?
Yes
Support for Detransition and Desistance
The specification contains no provisions for young people who desist or detransition. This is unconscionable given research evidence and our service experience. Genspect operates Beyond Trans because mainstream healthcare abandoned this population.
Through our service we have conducted 600+ meetings with 480+ participants from 43 countries desperately seeking help mainstream services refuse. They report encountering ideologically-captured clinicians responding to detransition distress by asking “what pronoun are you?” rather than addressing needs, dismissing medical complications, suggesting they might be “non-binary” rather than acknowledging harm.
Our data reveals the scale: 83% experience regret and doubt; 42% have medical complications; 47% experience suicidal ideation; 24% are estranged from family. Average time in transition is nine years, with some remaining decades before finding support to detransition.
The NHS cannot ethically implement services channeling young people toward medical pathways without comprehensive support for those experiencing regret, complications, or natural desistance. The specification must mandate: systematic longitudinal follow-up and outcome tracking; dedicated pathways for detransition support and medical complication management; clinician training enabling detransition support without ideological constraints; prospective research on desistance and detransition rates, timing, and predictive factors.
Evidence-Based Clinical Training
Our Beyond Trans service reveals systematic assessment failures internationally. All clinicians require comprehensive training: thoroughly exploring trauma, attachment difficulties, family dynamics as potential primary factors; recognizing autism creates discomfort with social gender expectations manifesting as gender distress without indicating opposite sex; understanding social contagion effects in adolescent female peer groups; assessing internalized homophobia in same-sex attracted youth; providing psychosocial interventions addressing root causes without presuming gender incongruence; conducting family therapy exploring dynamics without affirming predetermined outcomes.
Institutional Safeguarding and Legal Framework
The specification inadequately addresses how clinical guidance affects schools, sports, residential settings with safeguarding duties to all children. NHS clinicians cannot prescribe accommodations affecting other children’s privacy, safety, dignity without guidance addressing rights conflicts.
Clinical guidance must acknowledge legal constraints including sex-based protections under the Equality Act as clarified by the Supreme Court in For Women Scotland v Scottish Ministers (2025). Schools cannot lawfully compromise other children’s sex-based rights. Sports must maintain fair and safe competition. Residential facilities must protect all children. These considerations are central to ethical, lawful practice.
8. To what extent do you agree that the Equality and Health Inequalities Impact Assessment reflects the potential impact on equalities or health inequalities?
Disagree
The assessment has critical omissions fundamentally undermining its adequacy.
First, no analysis of impacts on other children in schools, sports, residential settings affected by social transition accommodation policies. These children have rights to privacy, safety, dignity that may conflict with requested accommodations, yet their interests receive no consideration.
Second, no examination of rights conflicts arising when accommodating one person’s gender reassignment characteristic may compromise sex-based protections for others under the Equality Act. The Supreme Court’s clarification in For Women Scotland v Scottish Ministers (2025) regarding sex in equality law is entirely absent.
Third, no consideration of disproportionate impact on same-sex attracted youth. Both research evidence and our Beyond Trans work strongly suggest many young people channeled toward medical transition are actually struggling with internalized homophobia rather than experiencing genuine gender incongruence. This represents safeguarding failure with particular impact on lesbian and gay youth.
Fourth, inadequate attention to safeguarding risks for vulnerable populations including autistic young people whose social and sensory difficulties may manifest as gender distress without indicating they are opposite sex, and those with trauma histories whose distress may represent trauma responses.
Fifth, no assessment of long-term health inequalities for young people undergoing irreversible medical interventions for what may be temporary, developmentally appropriate adolescent distress. Our Beyond Trans service demonstrates these impacts are substantial and require consideration.
The assessment fundamentally misframes issues by positioning cautious, evidence-based practice as potentially discriminatory. This framing is backwards. Protecting young people from poorly evidenced, irreversible medical interventions with documented potential for serious harm is the ethical standard of care. The framing serves ideological goals rather than children’s welfare and rights.